TMEFF1 is a novel transmembrane protein, containing two follisatin domains and an epidermal growth factorlike region. These structural domains suggest a role for TMEFF1 in growth factor signaling. TMEFF1 fused to enhanced green fluorescent protein revealed that TMEFF1 is expressed on the cell membrane. Northern analysis of normal human tissue showed that TMEFF1 is predominantly expressed in the brain. Study of cancer cell lines from different tissues including the brain, demonstrated moderate to low levels of TMEFF1 in most of these transformed cell lines. Furthermore, quantitative real-time RT-PCR analysis of 54 brain tumors showed that most of these tumors (96%) had lower levels of TMEFF1 expression than normal brain tissue. Interestingly, ectopic expression of TMEFF1 in brain cancer cells resulted in their growth inhibition. These data suggest that TMEFF1 may behave as a tumor suppressor gene in brain cancers.
Introduction
Glioblastomas are among the most malignant tumors for which no curative treatment exists. Growth factors and their signal transduction elements have been widely implicated in the molecular pathogenesis of brain tumors (Westermark and Westermark, 1995) . TMEFF1 is a novel transmembrane protein, composed of two follisatin domains and a unique epidermal growth factor (EGF)-like region. These structural domains suggest a role for TMEFF1 in the regulation of growth factor signaling either as a ligand precursor, a membranebound receptor or as a binding protein for growth factors. Previous studies characterized TMEFF1 expression in Xenopus laevis (Eib and Martens, 1996) and mice (Eib et al., 2000) , and found that it was predominantly expressed in the brain. Although a human ortholog has been cloned (Eib et al., 1998) , where it is expressed has not been studied.
In this report, we used Northern blot analysis and quantitative real-time PCR to assess TMEFF1 expression in normal human tissues, clinical brain cancer samples and cancer cell lines. We found that TMEFF1 was highly expressed in normal brain and poorly expressed in brain tumors. Moreover, forced expression of TMEFF1 resulted in inhibition of cell growth. These results suggest that TMEFF1 may have a suppressive role in brain carcinogensis.
Results

TMEFF1 expression in normal human tissue
Northern blot analysis of human tissues showed that TMEFF1 mRNA (3 kb) is expressed predominantly in the brain (Figure 1 ). Moderate levels were detected in heart, placenta and skeletal muscle, and weak expression was observed in the liver, kidney and pancreas.
TMEFF1 is localized to the cell membrane
The TMEFF1 coding region contains a single putative C-terminal transmembrane domain at residues 319-342. To determine where the protein is localized TMEFF1 cDNA was fused to enhanced green fluorescent protein (EGFP) in a mammalian expression vector. Fluorescent microscopy of transiently transfected U118 and NIH 3T3 cells demonstrated that TMEFF1 is expressed on the cell membrane (Figure 2 ).
TMEFF1 expression in cancer cell lines
We further tested TMEFF1 expression in cancer cell lines from different tissues (Figure 3) . Four brain cancer cell lines showed moderate (U343 and T98G) to low (U118 and U183) expression of TMEFF1. In the androgen-independent prostate cell lines DU145 and PC3, TMEFF1 was expressed at high and moderately low levels, respectively; and it was undetectable in the androgen-dependent prostate cell line LNCaP. Similarly, TMEFF1 was highly expressed in two estrogenindependent breast cancer cell lines MDA-MB-436 and MDA-MB-231, but low levels of TMEFF1 were found in the estrogen-responsive breast cancer cell line MCF7 and the normal breast cell line MCF-12A. TMEFF1 was highly expressed in two small lung cancer cell lines NCI-H446 and NCI-H526. In five other nonsmall lung cancer cell lines, TMEFF1 expression was moderate (NCI-H125) to low (NCI-H1299, NCI-H157, NCI-H520 and NCI-H157). In cell lines from a pancreatic cancer (PANC-1), hepatoma (HepG2) and leukemia (U937), TMEFF1 levels were in the middle range. Dihydrotestosterone and 17b-estradiol (10 -8 m, 2 days) were added to the androgen-responsive LNCaP prostate cancer cell line, and the estrogen-responsive MCF7 breast cancer cell line, respectively. No change in expression of TMEFF1 occurred (data not shown).
Forced expression of TMEFF1 inhibited proliferation of brain cancer cells
To test the effect of TMEFF1 on cell growth, we generated U118 glioblastoma cells that stably expressed prominent levels of TMEFF1. The growth rate of U118 cells that overexpressed TMEFF1 (U118 TM1) was slowed by approximately 41% compared to control cells (U118 N, stably transfected with the empty vector, Figure 1 TMEFF1 expression in normal tissues. A multiple tissue Northern blot was hybridized with radiolabeled TMEFF1 cDNA. The blot was stripped and rehybridized with a control a 2 P-dATPlabeled GAPDH Figure 2 TMEFF1 is expressed on the cell membrane. U118 brain cancer cells and NIH 3T3 cells transacted with a vector expressing either EGFP or EGFP/TMEFF1 were grown on cover slips and analysed by fluorescent microscopy ( Â 500 magnification and Â 1000 magnification, respectively)
Figure 3 TMEFF1 expression in cancer cell lines from various tissues. RNA was extracted from different cell lines and Northern blots were performed using radiolabeled TMEFF1 cDNA probe. The blots were rehybridized with GAPDH probe Expression of TMEFFI S Gery et al Figure 4 ). To test whether the EGF-like motiff is involved in the growth inhibition, a TMEFF1 deletion mutant of the EGF-like motiff was made leaving the transmembrane domain intact. This mutant gene (TM1-del) was stably introduced into U118 cells. The growth rate of U118 cells overexpressing this mutant (U118 TM1-del) was reduced 33% compared to the control cells ( Figure 4 ). These results suggest that the EGF-like motiff is not essential for the growth inhibition mediated by TMEFF1.
TMEFF1 expression was low in a large collection of primary brain cancer samples
In normal brain, TMEFF1 is expressed at high levels ( Figure 1 ). In contrast, TMEFF1 expression was low to moderate in the four brain cancer cell lines that we studied ( Figure 3 ). To establish whether levels of TMEFF1 expression were altered in brain cancers, real-time reverse transcription-PCR was used to quantify TMEFF1 levels in 54 primary brain tumors and four normal brain samples ( Figure 5 ). The mean expression of TMEFF1 in the four normal samples (456 relative expression units by real-time PCR) was considered as the normal level of expression in the brain. In 54% of the tumor samples TMEFF1 expression was extremely low (less than 50 relative expression units), 37% of tumor samples had low levels of TMEFF1 (between 50 and 300 relative expression units) and 6% of the tumor samples had high TMEFF1 expression (more than 600 relative units). Notably 60% of the extremely malignant glioblastoma (GBM) samples had very low TMEFF1 levels (mean 12 relative expression units), compared to only 12% of the astrocytoma samples that had very low TMEFF1 levels (mean 13 relative expression units). In 90% of the meningioma samples, TMEFF1 levels were also very low (mean 11 relative expression units).
Overall, more than 96% of the brain tumor samples had lower levels of TMEFF1 than the average expression level in the normal brain samples.
Discussion
In this report, we describe TMEFF1 expression in human cells. We demonstrated that an EGFP/TMEFF1 fusion protein was expressed on the cell membrane of brain cells. Northern analysis of normal human tissue showed that TMEFF1 is expressed predominantly in the brain and at lower levels in other tissues. High expression of TMEFF1 was detected in only several cancer cell lines from different origins including prostate, breast and lung. This gene displays a high degree of homology with TMEFF2 (Horie et al., 2000 : Glynne-Jones et al., 2001 . Both TMEFF1 and TMEFF2 are expressed at high levels in the brain, implicating their importance in the function of the normal central nervous system. However, whereas TMEFF2 is highly tissue specific and is expressed only in normal brain and prostate (Glynne-Jones et al., 2001; Gery et al., 2002) . TMEFF1 has a wider range of tissue expression. Although TMEFF1 function is largely unknown, its structural domains suggest that it may act as an inhibitor of growth factors. Follistatin domains have been identified in other proteins where they were shown to bind and neutralize different growth factors (Patthy and Nikolics, 1993; Kupprion et al., 1998; Patel, 1998) . In the EGF-like domain of TMEFF1, a critical arginine residue is replaced by a histidine. Replacement of this arginine results in a drastic decrease of EGF affinity to its receptor (Engler et al., 1990) . Overexpression of TMEFF1 in U118 cells resulted in their growth inhibition, suggesting that TMEFF1 acts as a negative regulator of growth in brain cells. A deletion in the EGF-like domain did not abolish the growth inhibitory phenotype suggesting that the follistatin domains are sufficient in causing growth inhibition. The function of the EGF-like domain requires further analysis. The question of whether TMEFF1 regulates either the cell cycle or contributes to cell loss, perhaps by apoptosis, is also unanswered by the current study.
To determine the relation of TMEFF1 expression to brain cancer, we measured TMEFF1 levels in a large series of brain tumors. All of the brain tumors in this study were derived from nonneuronal cells. In the vast majority of them (96%), as well as in four brain cancer cell lines TMEFF1 expression was low compared to its expression in normal brain cells. This was especially true for the highly proliferative, malignant GBM. These results suggest that TMEFF1 may behave as a tumor suppressor gene, and diminished expression of this protein may provide brain cancers with a growth advantage over normal cells in a significant number of individuals. This is consistent with our findings that forced expression of this protein in brain cancer cells decreases their growth. Two cancer cell lines originating from lung, which normally do not express TMEFF1, show high level of TMEFF1 expression. TMEFF1 expression was also moderately present in a pancreasderived tumor cell line, whereas in normal pancreas, TMEFF1 is weakly expressed. This suggests that while TMEFF1 has a growth suppressive effect in brain cancer cells, it might not behave in a similar fashion in lung and pancreas. More detailed studies need to be undertaken to understand more clearly the function of TMEFF1 in normal cells and its potential role in cancer.
Taken together, the results presented in this study suggest that deregulation of expression of TMEFF1 is associated with the transformed phenotype of brain cancers. As TMEFF1 is expressed on the cell membrane and is potentially involved with growth factor signaling, it could be considered as a drug target and for monitoring the development and treatment of brain cancers.
Materials and methods
Brain samples
The following samples were studied: four normal brains, 32 glioblastoma multiformes (GBMs), 12 astrocytomas and 10 meningiomas. All samples were snap-frozen in liquid nitrogen and stored at -701C until processing.
Cell culture
The following cell lines were used: glioma (U118, U183, U343, T98G), prostate cancer (LNCaP, PC3, DU145), breast cancer (MCF7, MDA-MB-436, MDA-MB-231), normal breast (MCF-12A), lung cancer (NCI-H446, NCI-H526, NCI-H125, NCI-H1299, NCI-H596, NCI-H520, NCI-H460), pancreas cancer (PANC-1), hepatoma (HepG2), acute myeloid leukemia (U937) and murine fibroblasts (NIH 3T3), which were obtained from the American Type Culture Collection and grown in the recommended medium and conditions.
Northern blot analysis and quantitative real-time RT-PCR
Total RNA was isolated from human brain samples and cell lines using TRIzol (Life Technologies. Inc.). For Northern analysis, 10 mg of total RNA was fractionated on 1.2% agarose 0 . Primers were synthesized by Life Technologies Inc. Probes were purchased from Applied Biosystems (Foster City, CA, USA) and were labeled with the reporter dye FAM in the 5 0 end and the quencher dye TAMRA in the 3 0 end. Amplification reactions were performed with the Universal Taqman PCR mastermix (Applied Biosystems) in triplicates in an iCycler iQt system (Biorad, Hercules, CA, USA). The thermal cycling conditions were as follows: 2 min at 501C, 10 min at 951C, followed by 45 cycles of 951C for 15 s and 601C for 1 min. To determine the relative expression level of each sample, additional reactions with four serial five-fold dilutions of DU145 cDNA were performed to generate a standard curve, which related the threshold cycle to the log input amount of template.
Transfections and cell proliferation assays cDNA coding for TMEFF1 was amplified from DU145 and cloned into the pcDNA3 expression vector (TM1, Invitogen). A deletion mutation in the EGF-like domain (amino acids 290-317) was generated by PCR and cloned into the same vector (TM1-del). U118 cells were transfected using the GenePORTERt Transfection Reagent (GTS Inc.) with 10 mg of either an empty pCDNA3 vector, TM1 or TM1-del. Stable U118 clones were obtained by selection in G418 (500 mg/ml). Real-Time RT-PCR confirmed expression of wild type and mutated TMEFF1. For MTT assays, cells were seeded in quadruplicate in 96-well plates at 1000 cells per well. Cell proliferation was assayed using the Cell Proliferation Kit I (MTT, Boehringer, Mannheim, Germany) according to the manufacturer's instructions.
Fluorescent microscopy
cDNA coding for TMEFF1 was amplified from DU145 cells and cloned into the pEGFP expression vector (Clontech). Either EGFP or EGFP/TMEFF1 plasmids were transfected into U118 brain cancer cells and NIH 3T3 cells as described above. Transfected cells were plated on cover slips and analysed 2 days after transfection by fluorescent microscopy using a 510 nm filter.
